Filing Flows › Madrigal Pharmaceuticals (MDGL) › Capital expenditures
Madrigal Pharmaceuticals (MDGL) capital expenditures by quarter
Madrigal Pharmaceuticals' capital expenditures were $3.9M in Q3 2026 (third quarter 2026), -8% from Q2 2026. Over the last 3 quarters it ranged from $857K (Q3 2025) to $4.3M (Q2 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.9M | -8% | +358% |
| Q2 2026 | $4.3M | +396% | — |
| Q3 2025 | $857K | — | — |
Q3 2026 at a glance
Madrigal Pharmaceuticals, Q3 2026: revenue $431M (+50% year over year), operating margin 13.0%, net earnings $55.4M, operating cash flow $121M. The chart follows the revenue to costs, profit and cash.
Questions
What is Madrigal Pharmaceuticals' capital expenditures?
Madrigal Pharmaceuticals' capital expenditures were $3.9M in Q3 2026 (third quarter 2026), -8% from Q2 2026.
How has Madrigal Pharmaceuticals' capital expenditures changed?
Over the last 3 quarters it ranged from $857K (Q3 2025) to $4.3M (Q2 2026).
Q3 2026 results → · How Madrigal Pharmaceuticals makes money →